Astria has made an exclusive licensing agreement with Kaken for the development and commercialisation rights of navenibart in Japan.

BeOne Medicines' investigational Bruton's tyrosine kinase (BTK) degrader, BGB-16673, has received priority medicines (PRIME) designation.

Supernus Pharmaceuticals has acquired Sage Therapeutics, strengthening its neuropsychiatry product portfolio. In June 2025, Supernus and Sage entered a definitive agreement for the acquisition, with ...

Trump doubles down on Most Favored Nation plan to target drug prices Major pharma manufacturers have a 29 September deadline to adjust their drug prices relative to other developed countries.

Tidmarsh will temporarily guide CBER’s regulatory activities while the FDA searches for a permanent department lead.

Dupixent sales spur Sanofi growth, but profits fall short Heavy investment into R&D for Dupixent’s successor meant earnings per share fell short of expectations.

African countries plan shift to healthcare funding autonomy amid aid cuts The WHO's director-general says leaders want self-reliance, with tobacco and alcohol tax rises on the cards to boost domestic ...

ViroCell Biologics has partnered AvenCell Therapeutics for development of new allogeneic CAR-T therapies to treat blood cancers.

The European Union (EU) will pay the US a tariff rate of 15% for pharmaceuticals as part of a new trade deal between the two countries, though uncertainty on future duties remains. The trade deal ...

The FDA has approved Ascendis Pharma’s Skytrofa (lonapegsomatropin-tcgd, developed as TransCon hGH) for the treatment of adults with GHD.

The HS market across the 7MM is forecast to grow from $1.84bn in 2024 to $7.83bn in 2034, according to GlobalData.

Sarepta has suffered another regulatory setback after the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on its Duchenne muscular ...